Abstract #0528

Contrast Agent Uptake Analysis at 3T for Pancreatic Cancer

Douglas Arthur Charles Kelley¹, Eric Collisson², Benjamin M Yeh³, Michael Ohliger³, and Zhen Wang³

¹Neuro Applications and Workflow, GE Healthcare, Corte Madera, CA, United States, ²Medicine, University of California, San Francisco, San Francisco, CA, United States, ³Radiology, University of California, San Francisco, San Francisco, CA, United States

Pancreatic cancer is highly desmoplastic and slowly takes up extracellular gadolinium based contrast agents during MR imaging. Quantitative estimation of gadolinium based contrast uptake in pancreas cancers may help assess the tumor stroma, which is implicated in tumor aggressiveness and treatment response. However, tissue motion and sensitivity inhomogeneity on abdominal MR scans present complications for quantitative analysis of contrast uptake. A new MR PET system with higher performance gradient and RF capabilities coupled with data-driven analysis methods allow robust estimation of contrast agent concentration in pancreatic cancer patients.

This abstract and the presentation materials are available to members only; a login is required.

Join Here